Works matching AU Prawjaeng, Juthamas

Results: 7

Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand: SGLT2i for Thai Diabetes with HF Patients: T. Kongmalai et al.

Published in:

PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 69, doi. 10.1007/s41669-024-00526-2

By:

Kongmalai, Tanawan;
Prawjaeng, Juthamas;
Hadnorntun, Phorntida;
Leelahavarong, Pattara;
Chaikledkaew, Usa;
Thakkinstian, Ammarin;
Srinonprasert, Varalak

Publication type:

Article

Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic.

Published in:

European Journal of Health Economics, 2023, v. 24, n. 5, p. 735, doi. 10.1007/s10198-022-01505-2

By:

Wang, Yi;
Luangasanatip, Nantasit;
Pan–ngum, Wirichada;
Isaranuwatchai, Wanrudee;
Prawjaeng, Juthamas;
Saralamba, Sompob;
Painter, Christopher;
Briones, Jamaica Roanne;
Teerawattananon, Yot

Publication type:

Article

Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis: A Cost-Utility Analysis of Onasemnogene Abeparvovec and Risdiplam for SMA Treatment: S. Khuntha et al.

Published in:

Applied Health Economics & Health Policy, 2025, v. 23, n. 2, p. 277, doi. 10.1007/s40258-024-00915-y

By:

Khuntha, Sarayuth;
Prawjaeng, Juthamas;
Ponragdee, Kunnatee;
Sanmaneechai, Oranee;
Srinonprasert, Varalak;
Leelahavarong, Pattara

Publication type:

Article

Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines.

Published in:

Applied Health Economics & Health Policy, 2021, v. 19, n. 4, p. 463, doi. 10.1007/s40258-021-00661-5

By:

Painter, Chris;
Isaranuwatchai, Wanrudee;
Prawjaeng, Juthamas;
Wee, Hwee Lin;
Chua, Brandon Wen Bing;
Huynh, Vinh Anh;
Lou, Jing;
Goh, Fang Ting;
Luangasanatip, Nantasit;
Pan-Ngum, Wirichada;
Yi, Wang;
Clapham, Hannah;
Teerawattananon, Yot

Publication type:

Article

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.

Published in:

BMC Health Services Research, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12913-023-09595-1

By:

Prawjaeng, Juthamas;
Leelahavarong, Pattara;
Budtarad, Nuttakarn;
Pilasant, Songyot;
Chanjam, Chonticha;
Katchamart, Wanruchada;
Narongroeknawin, Pongthorn;
Kitumnuaypong, Tasanee

Publication type:

Article

Binding and neutralizing antibody levels and vaccine efficacy/effectiveness compared between heterologous and homologous primary series COVID-19 vaccination: A systematic review and meta-analysis.

Published in:

Asian Pacific Journal of Allergy & Immunology, 2022, v. 40, n. 4, p. 321, doi. 10.12932/ap-121122-1501

By:

Angkasekwinai, Nasikarn;
Prawjaeng, Juthamas;
Leelahavarong, Pattara;
Khuntha, Sarayuth;
Pheerapanyawaranun, Chatkamol;
Chitpim, Natthakan;
Srinonprasert, Varalak;
Chokephaibulkit, Kulkanya

Publication type:

Article

A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand.

Published in:

Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-024-81747-7

By:

Chitpim, Natthakan;
Leelahavarong, Pattara;
Prawjaeng, Juthamas;
Ittiphisit, Sakditat;
Srinonprasert, Varalak;
Kongmalai, Tanawan

Publication type:

Article